SI1549333T1 - Analogi kompstatina z izboljĺ ano aktivnostjo - Google Patents

Analogi kompstatina z izboljĺ ano aktivnostjo

Info

Publication number
SI1549333T1
SI1549333T1 SI200332088T SI200332088T SI1549333T1 SI 1549333 T1 SI1549333 T1 SI 1549333T1 SI 200332088 T SI200332088 T SI 200332088T SI 200332088 T SI200332088 T SI 200332088T SI 1549333 T1 SI1549333 T1 SI 1549333T1
Authority
SI
Slovenia
Prior art keywords
improved activity
compounds
peptides
disclosed
compstatin analogues
Prior art date
Application number
SI200332088T
Other languages
English (en)
Inventor
John D Lambris
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SI1549333T1 publication Critical patent/SI1549333T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200332088T 2002-09-20 2003-09-22 Analogi kompstatina z izboljĺ ano aktivnostjo SI1549333T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41222002P 2002-09-20 2002-09-20
PCT/US2003/029653 WO2004026328A1 (en) 2002-09-20 2003-09-22 Compstatin analogs with improved activity
EP03759343A EP1549333B1 (en) 2002-09-20 2003-09-22 Compstatin analogues with improved activity

Publications (1)

Publication Number Publication Date
SI1549333T1 true SI1549333T1 (sl) 2012-02-29

Family

ID=32030834

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332088T SI1549333T1 (sl) 2002-09-20 2003-09-22 Analogi kompstatina z izboljĺ ano aktivnostjo

Country Status (13)

Country Link
US (4) US7989589B2 (sl)
EP (3) EP1549333B1 (sl)
JP (3) JP4614222B2 (sl)
AT (1) ATE525082T1 (sl)
AU (1) AU2003275075A1 (sl)
CA (2) CA2502690C (sl)
CY (1) CY1112198T1 (sl)
DK (1) DK1549333T3 (sl)
ES (1) ES2373649T3 (sl)
HK (2) HK1156862A1 (sl)
PT (1) PT1549333E (sl)
SI (1) SI1549333T1 (sl)
WO (1) WO2004026328A1 (sl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2502690C (en) * 2002-09-20 2014-01-28 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
WO2005118020A1 (en) * 2004-04-21 2005-12-15 Allvivo, Inc. Surface coating comprising bioactive compound
CA2625206C (en) * 2005-10-08 2021-12-07 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
DK1960422T3 (da) 2005-11-28 2012-08-13 Univ Pennsylvania Meget virksomme compstatin-analoger
AU2013200981B2 (en) * 2005-11-28 2016-01-14 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
US8442776B2 (en) 2007-06-08 2013-05-14 The Trustees Of The University Of Pennsylvania Structure of compstatin-C3 complex and use for rational drug design
US8563259B2 (en) 2007-06-29 2013-10-22 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
JP2010540654A (ja) * 2007-10-02 2010-12-24 ポテンシア ファーマシューティカルズ， インコーポレイテッド ゲルからのコンプスタチンアナログの持続的送達
US10632170B2 (en) 2008-02-19 2020-04-28 The Trustees Of The University Of Pennsylvania Administration of compstatin to an individual for the treatment of a tumor
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
US9180160B2 (en) 2008-08-20 2015-11-10 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury from intracerebral hemorrhage
US8445190B2 (en) 2008-09-30 2013-05-21 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
JP5882890B2 (ja) * 2009-05-01 2016-03-09 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ペプチド骨格およびｃ末端改変を持つ改変したコンプスタチン
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
US20110104154A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
WO2012095519A1 (en) 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
WO2012135624A1 (en) 2011-04-01 2012-10-04 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
RU2653439C9 (ru) 2011-05-11 2018-10-16 Апеллис Фармасьютикалс, Инк. Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
EP3524258A1 (en) 2011-06-22 2019-08-14 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US9630992B2 (en) 2011-09-07 2017-04-25 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
WO2014078734A2 (en) * 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
DK3660033T5 (da) 2012-11-15 2022-06-27 Apellis Pharmaceuticals Inc Langtidsvirkende compstatinanaloger og tilhørende sammensætninger og fremgangsmåder
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
JP6710638B2 (ja) 2013-12-12 2020-06-17 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分ｉＲＮＡ組成物及びその使用方法
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2015142701A1 (en) 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
JP6968787B2 (ja) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2018187813A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
EP3704252A1 (en) 2017-11-01 2020-09-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
EP3759120A1 (en) 2018-02-27 2021-01-06 Zp Spv 3 K/S Compstatin analogues and their medical uses
RU2020136249A (ru) 2018-04-06 2022-05-06 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Аналоги компстатина с увеличенной растворимостью и улучшенными фармакокинетическими свойствами
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
KR20210057086A (ko) 2018-09-06 2021-05-20 아칠리온 파르마세우티칼스 인코포레이티드 다니코판의 형태체 형태
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
EP4272751A3 (en) 2019-08-27 2024-02-14 Zp Spv 3 K/S Compstatin analogues and their medical uses
CN115176004A (zh) 2019-10-22 2022-10-11 阿尔尼拉姆医药品有限公司 补体成分C3 iRNA组合物及其使用方法
EP4114947A1 (en) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
EP4142738A1 (en) 2020-04-30 2023-03-08 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
BR112022022980A2 (pt) 2020-05-12 2022-12-20 Alexion Pharma Inc Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna
CN116209671A (zh) 2020-07-16 2023-06-02 西兰制药第三特殊目的公司 补体因子c3的抑制剂及其医学用途
WO2022150260A1 (en) 2021-01-05 2022-07-14 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
WO2023076451A1 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US4807097A (en) * 1986-05-14 1989-02-21 Gammache Richard J Miniature flashlight
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5167960A (en) 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
WO1991016345A1 (en) 1990-04-23 1991-10-31 Rijksuniversiteit Te Utrecht Cyclic peptides and their use
JPH09510088A (ja) 1994-03-03 1997-10-14 アレクション・ファーマシューティカル・インク 最終補体インヒビター融合遺伝子およびタンパク質
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
US6319897B1 (en) * 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
US6221621B1 (en) * 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
AU4648197A (en) 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
AU3485999A (en) 1998-04-10 1999-11-01 Mayo Foundation For Medical Education And Research Neo-tryptophan
CA2502690C (en) * 2002-09-20 2014-01-28 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
DK1960422T3 (da) * 2005-11-28 2012-08-13 Univ Pennsylvania Meget virksomme compstatin-analoger

Also Published As

Publication number Publication date
US8883413B2 (en) 2014-11-11
JP2013138673A (ja) 2013-07-18
EP1549333A1 (en) 2005-07-06
EP2311479B1 (en) 2014-07-23
CA2502690A1 (en) 2004-04-01
EP1549333B1 (en) 2011-09-21
JP5860573B2 (ja) 2016-02-16
DK1549333T3 (da) 2012-01-16
WO2004026328A1 (en) 2004-04-01
EP1549333A4 (en) 2008-05-28
ATE525082T1 (de) 2011-10-15
JP2006505254A (ja) 2006-02-16
CA2502690C (en) 2014-01-28
JP4614222B2 (ja) 2011-01-19
CY1112198T1 (el) 2015-12-09
JP2010280688A (ja) 2010-12-16
US20180118785A1 (en) 2018-05-03
US20100222550A1 (en) 2010-09-02
PT1549333E (pt) 2012-01-03
ES2373649T3 (es) 2012-02-07
US20170190741A9 (en) 2017-07-06
HK1156862A1 (en) 2012-06-22
CA2833202A1 (en) 2004-04-01
US20150158913A1 (en) 2015-06-11
EP2311480B1 (en) 2013-06-26
EP2311480A1 (en) 2011-04-20
HK1156860A1 (en) 2012-06-22
EP2311479A1 (en) 2011-04-20
CA2833202C (en) 2017-08-01
US20110275150A1 (en) 2011-11-10
AU2003275075A1 (en) 2004-04-08
US7989589B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
SI1549333T1 (sl) Analogi kompstatina z izboljĺ ano aktivnostjo
WO2007062249A3 (en) Potent compstatin analogs
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
IL172403A0 (en) D-amino acid peptides
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE
AUPP472398A0 (en) Protease susceptibility II
ATE362487T1 (de) N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
AU2003223923A1 (en) Peptide nucleic acid conjugates with transporter peptides
WO2002046407A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
ATE375360T1 (de) Peptide mit inhibierender aktivität zur produktion von stickstoffmonoxid
AU2003217174A8 (en) Novel variants of rankl protein
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
AU2003295435A1 (en) Biological carriers for the delivery of proteins or peptides
WO2001081412A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
WO2001081413A3 (en) Isolated human transporter proteins, nucleic acids and uses thereof
WO2002022678A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2001000655A3 (en) Therapeutic peptides derived from subsequences of bpi
WO2002033086A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002046217A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002020757A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002024748A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002077261A3 (en) Human potassium channel
WO2001088136A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof